TriangleNCT03409614 · OUTCOME
Part 1: Estimated Survival Probability
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Estimated percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 12 months, 18 months, 24 months
What was measured
OS rate at a landmark (12, 18, and 24 months) was defined as the Kaplan-Meier (K-M) estimated probability of participants who survived due to any cause at the landmark after randomization.
Analysis population: Part 1 participants only
Groups in this outcome
Part 1: Cemiplimab + Chemotherapy
Participants received cemiplimab plus platinum-based doublet chemotherapy
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab
Part 1: Chemotherapy
Participants received platinum-based doublet chemotherapy
| Group | Source count |
|---|---|
| Part 1: Cemiplimab + Chemotherapy | 108 |
| Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | 109 |
| Part 1: Chemotherapy | 106 |
Reported measurements
12 months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: Cemiplimab + Chemotherapy | 59.4 | Not reported | 48.9 | 68.4 | Not reported |
| Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | 68.5 | Not reported | 58.4 | 76.6 | Not reported |
| Part 1: Chemotherapy | 54.0 | Not reported | 43.6 | 63.3 | Not reported |
18 months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: Cemiplimab + Chemotherapy | 47.5 | Not reported | 37.2 | 57.1 | Not reported |
| Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | 51.9 | Not reported | 41.7 | 61.2 | Not reported |
| Part 1: Chemotherapy | 39.7 | Not reported | 29.8 | 49.4 | Not reported |
24 months
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: Cemiplimab + Chemotherapy | 41.0 | Not reported | 31.1 | 50.7 | Not reported |
| Part 1: Cemiplimab+AbbrevChemo+Ipilimumab | 42.3 | Not reported | 32.4 | 51.9 | Not reported |
| Part 1: Chemotherapy | 26.5 | Not reported | 18.0 | 35.7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 48.9
- upper Limit
- 68.4
- value
- 59.4
- group Id
- OG001
- lower Limit
- 58.4
- upper Limit
- 76.6
- value
- 68.5
- group Id
- OG002
- lower Limit
- 43.6
- upper Limit
- 63.3
- value
- 54.0
- title
- 12 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 37.2
- upper Limit
- 57.1
- value
- 47.5
- group Id
- OG001
- lower Limit
- 41.7
- upper Limit
- 61.2
- value
- 51.9
- group Id
- OG002
- lower Limit
- 29.8
- upper Limit
- 49.4
- value
- 39.7
- title
- 18 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 31.1
- upper Limit
- 50.7
- value
- 41.0
- group Id
- OG001
- lower Limit
- 32.4
- upper Limit
- 51.9
- value
- 42.3
- group Id
- OG002
- lower Limit
- 18.0
- upper Limit
- 35.7
- value
- 26.5
- title
- 24 months
- denoms
- counts
- group Id
- OG000
- value
- 108
- group Id
- OG001
- value
- 109
- group Id
- OG002
- value
- 106
- units
- Participants
- description
- OS rate at a landmark (12, 18, and 24 months) was defined as the Kaplan-Meier (K-M) estimated probability of participants who survived due to any cause at the landmark after randomization.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received cemiplimab plus platinum-based doublet chemotherapy
- id
- OG000
- title
- Part 1: Cemiplimab + Chemotherapy
- description
- Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab
- id
- OG001
- title
- Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
- description
- Participants received platinum-based doublet chemotherapy
- id
- OG002
- title
- Part 1: Chemotherapy
- param Type
- NUMBER
- population Description
- Part 1 participants only
- reporting Status
- POSTED
- time Frame
- 12 months, 18 months, 24 months
- title
- Part 1: Estimated Survival Probability
- type
- SECONDARY
- unit Of Measure
- Estimated percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice